News | EU-CardioRNA granted €3.88 million by the European Commission for COVID-19 research
The EU-CardioRNA (Catalyzing transcriptomics research in cardiovascular disease) COST Action has been awarded the COVIRNA project to improve surveillance and care of COVID-19 patients. The Action which is halfway through its four years, submitted a proposal with a consortium of 15 partners from healthcare, academia and industry from 12 European countries.
Read the full article here →
Annual Report 2020 | Rapid response for cardio COVID testing
Thanks to a COST Action network, a rapid diagnostic test for COVID-19 patients is being developed. The COVIRNA project is one of 23 research proposals selected under the Horizon 2020 call for 'Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems'. The project was inspired by the successful and ongoing COST Action 'Catalyzing transcriptomics research in cardiovascular disease (EU-CardioRNA)'.
See page 24 of the report →